CASC3 and plasma cell leukemia: The implementation of BTZ in Plasma Cell Leukemia (PCL) as an induction therapy in combination with chemotherapy exhibited a 79 % overall response rate (ORR) (Jurczyszyn et al., 2018[69]; Teachey et al., 2020[147]).